Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.67 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CLK1 | P49759 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.54 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.54 |
| ▸ | NAT1 | P18440 | 1/20 | 0.54 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 10/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7463867 | 0.82 | PIM1 (0.68) | IGF1RCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL8616061 | 0.81 | PIM1 (0.66) | IGF1RCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL6785380 | 0.80 | IGF1R (1.00) | IGF1RNAT1ADAMTS5PIM1PIM2 | |
| SCHEMBL6785383 | 0.80 | IGF1R (1.00) | IGF1RNAT1ADAMTS5PIM1PIM2 | |
| SCHEMBL4156417 | 0.75 | CSNK2A2 (0.65) | CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A | |
| SCHEMBL7519991 | 0.75 | CSNK2A2 (0.65) | IGF1RCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL7464574 | 0.74 | PIM1 (0.68) | IGF1RCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL6860827 | 0.74 | PIM1 (0.66) | IGF1RCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL6860373 | 0.74 | PIM1 (0.66) | IGF1RCSNK2A2CLK1CSNK2BCSNK2A1 | |
| SCHEMBL5673273 | 0.74 | TDP1 (0.66) | CSNK2A2CLK1CSNK2BCSNK2A1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727267-B2 | COMPOUND FOR USE IN THE TREATMENT OF VIRAL DISEASES | TULARIK INC. | 2004-04-27 | — | — | US | disclosed |
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | TULARIK INC. (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2001077091-A2 | NS5B HCV POLYMERASE INHIBITORS | TULARIK INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | POLRMT, RNASE1, POLI | IGF1R 4706/4885CSNK2A2 2600/4885CLK1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.